Nick discusses these themes and more in Citeline’s In Vivo Strategic Intent podcast, including executive succession, board effectiveness, interim leadership and the changing global market for life sciences talent.

Listen to the full episode and read the accompanying article on In Vivo → HERE

A biotech company can have outstanding science, strong intellectual property and access to capital — and still fail to translate that potential into value.

After more than 30 years of placing leaders across biotechnology and pharmaceuticals, RSA Group Executive Chairman Nick Stephens describes three fundamentals behind a successful biotech business:

“You need some good IP, you need access to sufficient capital, and you need the right people to deploy that capital at pace to bring new medicines to patients.”

The first two receive enormous scrutiny. The third can be much harder to assess.

That question sits at the centre of Nick’s recent appearance on Citeline’s In Vivo Strategic Intent podcast, where he discusses leadership transitions, board composition, executive hiring and the changing life sciences talent market.

Leadership must evolve with the company

The leadership team needed to establish a biotech company is not necessarily the team required to take it through clinical development, financing, international expansion or commercialisation.

This is particularly relevant for founder-led companies.

A founder-scientist may be ideally placed to establish the business, develop its scientific proposition and attract its first investors. As the company grows, however, the requirements of the CEO role can change considerably.

The challenge is recognising when the needs of the position have moved beyond the strengths of the individual currently occupying it.

Emotional attachment can make these decisions difficult. Founders have often devoted years to their science, while boards and investors develop close relationships with management teams.

But leadership should not be treated as a fixed asset. If the company changes, its leadership requirements should be reassessed with it.

Transparency and regular self-reflection can help boards identify these gaps before they become serious business problems.

The risk of avoiding change

Leadership problems are not always difficult to identify. Acting on them can be.

Changing a CEO or restructuring a board creates disruption, cost and perceived risk. Maintaining the status quo can therefore feel like the safer option.

As Nick explains:

“A lot of people are hanging onto boards and not developing them because of 1) the perceived personal risk, and 2) the perceived risk and cost of change.”

But avoiding change carries its own cost.

For biotech companies operating with finite capital and critical development milestones, the wrong leadership structure can contribute to delayed programmes, poor allocation of investment, unsuccessful fundraising and missed strategic opportunities.

Boards should therefore ask not only whether their current leadership team is performing, but whether it is the right leadership team for the company's next stage.

Interim and fractional leadership

The growing use of interim and fractional executives provides companies with another way to manage these transitions.

Not every leadership gap requires an immediate permanent appointment.

A company approaching a financing event, clinical milestone, transaction, restructuring or commercial transition may need specialist leadership for a defined period.

Interim and fractional executives can provide that capability quickly while giving the board time to determine what the organisation will require longer term.

This can be particularly valuable when circumstances are changing quickly. Instead of making a permanent appointment simply because a vacancy exists, companies can introduce the expertise they need now while making a more considered decision about the future.

Boards must evolve too

Leadership succession should not stop at the executive team.

The expertise required from a board during the formation of a company may be very different from what is required during clinical development, institutional financing or commercialisation.

A high-performing board must therefore be prepared to reassess its own composition.

Experience and continuity remain valuable, but neither should prevent change when the organisation requires different capabilities.

The strongest boards are not necessarily those that remain unchanged. They are those willing to recognise when the next stage of the company requires something different.

Looking beyond the “shiny badge”

Nick also challenges one of the most common approaches to reducing perceived recruitment risk: hiring executives because of the organisations on their CV.

He describes the temptation to choose someone with a:

“shiny badge… somebody who’s got a pedigree in an organization that’s made an awful lot of money.”

Previous success matters, but context matters just as much.

An executive who has succeeded inside a large, well-capitalised pharmaceutical company will not automatically succeed in an early-stage biotech operating with limited resources and a much smaller leadership structure.

Similarly, choosing someone simply because they have previously held the same title can favour familiarity over capability.

Executive selection should instead focus on the challenges ahead: What does this company need to achieve next, and which individual is best equipped to make that happen?

As Nick puts it:

“People will always claim, ‘If success will be down to me, failure is due to the market.’ That’s not true. It’s a blend of both.”

Leadership as strategic risk management

Ultimately, leadership planning is about anticipating problems before they become critical.

Biotech companies spend significant time scrutinising their science, capital requirements and development strategy. The same discipline should be applied to the people responsible for delivering them.

Boards should regularly consider whether their leadership structure reflects where the company is going — rather than simply where it has been.

That brings the discussion back to Nick’s three fundamentals: IP, capital and people.

Strong science creates the opportunity. Capital provides the means to pursue it. But the right people are required to turn both into progress.